Recent Updates — TECH
Bio-Techne shareholders approved the Merger Agreement with Merck KGaA, Darmstadt, Germany at a special meeting held on September 23, 2026. The proposal received 121,929,544 votes in favor against 1,208,817, representing approval by holders of 78.55% of outstanding shares as of the August 11 record date. The HSR waiting period expired on September 18, 2026, clearing a key regulatory hurdle. Bio-Techne expects the transaction to close in late 2026 or early 2027, pending remaining regulatory approvals and customary conditions. Bio-Techne is a global life sciences company providing reagents, analytical instruments, and diagnostic products.
Bio-Techne filed a supplemental disclosure regarding its proposed merger with Merck KGaA to address litigation alleging the Proxy Statement misrepresented or omitted material information. A shareholder lawsuit seeks to enjoin the special meeting scheduled for September 23, 2026. The filing updates financial data used by Goldman Sachs in its fairness opinion, citing approximately $421 million in LTM Adjusted EBITDA (Core) as of March 31, 2026, and total debt of approximately $200 million. Bio-Techne operates in the life sciences research tools industry.
Bio-Techne Corporation reported fourth quarter fiscal 2026 results ending June 30, 2026. Net sales increased 1% to $321.2 million, with organic revenue up 3%. GAAP diluted EPS rose to $0.35 from a loss of $(0.11) in the prior year period, while adjusted diluted EPS was $0.52. Full-year net sales remained flat at $1.2 billion, and full-year GAAP diluted EPS increased to $1.16 from $0.46. The company reiterated its agreement to be acquired by Merck KGaA for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. Bio-Techne also announced a quarterly cash dividend of $0.08 per share, payable September 4, 2026, to shareholders of record on August 24, 2026. The company operates in the life sciences industry, providing reagents, analytical instruments, and precision diagnostics.
Bio-Techne Corporation entered into a merger agreement with Merck KGaA, Darmstadt, Germany, to be acquired for $73.00 per share in cash. The transaction is subject to shareholder approval and customary closing conditions. Bio-Techne Corporation is a life sciences company that provides tools and reagents for research and clinical diagnostics.
Bio-Techne Corporation and Merck KGaA, Darmstadt, Germany, have executed an Agreement and Plan of Merger, announcing a proposed acquisition of Bio-Techne by Merck KGaA. The transaction is subject to shareholder approval and several conditions. Bio-Techne is a life sciences tools and reagents company providing biological and biological-related products for research and clinical diagnostics.